Day: June 18, 2021

All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO window of expected normal developmentThe majority of children (82%) treated in STR1VE-EU achieved developmental motor milestones not observed in the natural history of SMA Type 1, including patients with more severe diseaseMore than 1,200 patients have now been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting1Basel, June 18, 2021 – Novartis today announced data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA). New late-breaker data from the completed...

SOUTH SAN FRANCISCO, Calif., June 18, 2021 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share, which includes 568,181 shares issued and sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares of common stock were offered by RAPT. The aggregate gross proceeds to RAPT from the offering were approximately $143.7 million, before deducting underwriting discounts and commissions...

ZURICH, June 18, 2021 (GLOBE NEWSWIRE) — Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) has successfully extended the subordinated convertible loan agreement of CHF 900,000 dated 8 March 2021 to CHF 1,650,000 thereby granting Achiko an additional CHF 750,000 to be used on product development, sales and marketing and essential working capital with focus on AptameX and Teman Sehat product launches in Indonesia in early Q3 2021. The additional amount of the convertible loan comes attached with an issuance of an additional 1,500,000 warrants. Each warrant confers the right to purchase one registered share of the Company, has an exercise period between 2 November 2021 and the 360th day after the date of issuance of the warrants and with an exercise price of CHF 0.23 (subject to customary adjustments). Following on...

PRESS RELEASEJune 18, 2021Implementation of the share buyback programme Boulogne-Billancourt, June 18, 2021 – As part of the implementation of its share buyback program, Renault Group has entrusted an investment services provider with a mandate to purchase a maximum number of 1,010,000 Renault shares. The purpose of such share buyback is to cover Renault’s obligations towards the beneficiaries of performance shares or any long-term incentive plan implemented for the benefit of the Group’s employees and corporate officers. Depending on market conditions, the purchase will be carried out over a period running from 21 June 2021 up to and including 25 June 2021. The description of the share buyback program, as authorized by the Annual General Meeting of April 23, 2021 under the 20th resolution, is detailed on pages 446-447...

PRESS RELEASEParis, 18 June 2021 (5:45pm) ADLPartner / ADLPerformance: Combined general meeting on 18 June 2021 Due to the Covid-19 epidemic, the combined general meeting held today as a closed session, chaired by Mr. Bertrand Laurioz, ADLPerformance Group Chairman and CEO. The shareholders, who voted by post, by email or by proxy, approved all 13 of the resolutions put forward by the Group’s Board of Directors. Approval of the full-year accounts for 2020 The general meeting approved the corporate and consolidated financial statements for 2020. Dividend payout The General Meeting decided to pay out a dividend of €0.81 per share for fiscal year 2020, in accordance with the Board of Directors proposal. Its ex-dividend date has been set for 23 June 2021 and it will be released for payment on 25 June. Other resolutions The Company’s shareholders...

VINCIT OYJ PÖRSSI-ILMOITUS 18.6.2021                VINCIT OYJ: OMIEN OSAKKEIDEN HANKINTA 18.6.2021         Helsingin Pörssi             Päivämäärä 18.6.2021    Pörssikauppa Osto    Osakelaji VINCIT    Osakemäärä 5,000 osaketta  Keskihinta/ osake 9.8971 EUR  Kokonaishinta 49,485.50 EUR                Yhtiön hallussa olevat omat osakkeet 18.6.2021  tehtyjen kauppojen jälkeen: 219 841 kpl.                  Vincit Oyj:n puolesta             Nordea Pankki Oyj                    Janne Sarvikivi Sami Huttunen           Lisätietoja:      Vincit Oyj, toimitusjohtaja Mikko Kuitunen    p. 040 589 8316                    www.vincit.com             AttachmentVINCIT_18.6_trades

– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET – HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 18, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China (“NMPA”) for the treatment of advanced pancreatic neuroendocrine tumors (“pNETs”). This follows the approval of surufatinib in China in December 2020 for the treatment of advanced extra-pancreatic (non-pancreatic) neuroendocrine tumors (“epNETs”). The Company was made aware through the website of the NMPA that surufatinib’s approval...

Scheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) — Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented. The Special Meeting will be reconvened at 10:00 a.m. Eastern time on June 30, 2021 to allow more opportunity for stockholders to vote on the proposals described in the Company’s definitive...

NEWPORT NEWS, Va., June 18, 2021 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE:HII) announced today that Jason Sutton has been promoted to chief information officer for its Newport News Shipbuilding division, effective June 21. Sutton will be responsible for all aspects of information technology to enable Newport News to establish IT priorities and meet strategic objectives. Sutton will guide the day-to-day leadership of all information systems, while ensuring the appropriate alignment to enterprise cybersecurity and IT goals. Additionally, he will lead the HII enterprise cybersecurity and IT organizational and leadership change model to build high-performing teams. Sutton will report to Bharat Amin, HII’s executive vice president and chief information officer, for cybersecurity and IT-related activities and also will...

May 2021 Sales price Group sales prices development as followsQ1           2017       1,24 EUR/kg live weight (Jan 1,23 EUR – Feb 1,24 EUR – Marts 1,26 EUR) Q2           2017       1,41 EUR/kg live weight (Apr 1,43 EUR – May 1,41 EUR – June 1,39 EUR) Q3           2017       1,30 EUR/kg live weight (July 1,32 EUR – Aug 1,30 EUR – Sept 1,29 EUR) Q4           2017       1,13 EUR/kg live weight (Oct 1,17 EUR – Nov 1,12 EUR – Dec 1,11 EUR) Q1           2018       1,09 EUR/kg live weight (Jan 1,07 EUR – Feb 1,08 EUR – Marts 1,12 EUR) Q2           2018       1,17 EUR/kg live weight (April 1,18 EUR – May 1,15 EUR – June 1,18 EUR) Q3           2018       1,19 EUR/kg live weight (July 1,19 EUR, August 1,18 EUR, September 1,19) Q4           2018       1,10 EUR/kg live weight (Oct 1,11 EUR – Nov 1,12 EUR – Dec 1,07 EUR) Q1           2019      ...